18 Nov 2026

Boltz announces its £85m Series A round led by Bessemer Venture Partners to build AI models for molecular design

Boltz is building a platform of models for molecular design. It offers Boltz Lab, including the BoltzMol-1 and BoltzProt-1 models, so scientists at pharmaceutical, biotech and industrial companies can design molecules.

Boltz, a platform of models for molecular design, has raised £85 million in a Series A round. The round was led by Bessemer Venture Partners, with existing investors Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures, and new investors Greycroft, F-Prime Capital, Hummingbird and Benchling.

In January, Boltz launched Boltz Lab, a platform where scientists and AI agents can design proteins and small molecules in minutes rather than days. Its free models, Boltz-1, Boltz-2 and BoltzGen, have been downloaded more than 5 million times and used by over 100,000 scientists in universities and industry. Using these models, it discovered small-molecule hits and designed protein binders for a majority of the challenging targets it pursued, at a fraction of the time and cost that traditional methods or previous models would have required.

The platform is used by pharmaceutical, biotech and industrial companies, including six of the world’s 20 largest drugmakers. Boltz has partnerships with Pfizer, GSK, Takeda and Bristol Myers Squibb, and with dsm-firmenich outside pharma. Since June, usage among paying customers has grown 50-fold. Since launching from stealth in 2025 with a £21 million seed round, Boltz has grown from a small group of MIT researchers to a team of 40 scientists and engineers.

The funding will help Boltz invest deeply into compute and data, meet growing demand from its partners and expand its team. Its long-term goal is a world where a scientist can go from a therapeutic hypothesis to a human-ready molecule without leaving their computer.

Powered by
NatWestSageHarmonicNovus

Similar articles